Evidence map›Paper›PMID 36237267›Full record

ArticleTranslational cancer research2022

Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer.

Martin Svaton, Marie Drosslerova, Ondrej Fischer, Miloslav Marel, Michal Hrnciarik, Ondrej Venclicek, Petr Zuna, Michal Svoboda, Jiri Blazek, Monika Bratova and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Martin SvatonDepartment of Pneumology and Phthisiology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Marie DrosslerovaDepartment of Respiratory Medicine, Thomayer Hospital, Prague, Czech Republic.
Ondrej FischerDepartment of Respiratory Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic.
Miloslav MarelDepartment of Pneumology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
Michal HrnciarikDepartment of Pneumology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
Ondrej VenclicekDepartment of Respiratory Diseases, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic.
Petr ZunaDepartment of Pneumology and Thoracic Surgery, Bulovka Hospital, Prague, Czech Republic.
Michal SvobodaInstitute of Biostatistics and Analyses, Ltd. Brno, Czech Republic.
Jiri BlazekDepartment of Pneumology and Phthisiology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Monika BratovaDepartment of Respiratory Diseases, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic.
Andrea MullerovaDepartment of Respiratory Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic.
Bohuslava VankovaDepartment of Pathology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Daniel KrejciDepartment of Pneumology and Thoracic Surgery, Bulovka Hospital, Prague, Czech Republic.
Charles University · CZFakultní nemocnice Bulovka · CZPalacký University Olomouc · CZUniversity Hospital Brno · CZThomayer University Hospital · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Programmed death-ligand 1 (PD-L1) expression is a standard predictor in the selection of immunotherapy for locally advanced/advanced non-small cell lung cancer (NSCLC). However, comedication with corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs) may influence the effectiveness of this treatment as documented in several previous studies. Due to certain molecular linkages between PD-L1 and corticosteroids or NSAIDs, we therefore addressed the question of whether there is a relationship between PD-L1 expression in NSCLC and the use of this comedication. Methods: This is a retrospective study using the Czech tumor registry LUng CAncer focuS (LUCAS), from which patient data were drawn. Independence of two categorical parameters was tested by Pearson's chi-square test. Results: In our group of 1,148 patients, we observed no significant relationship between PD-L1 expression and the use of corticosteroids or NSAIDs. Conclusions: According to our data, treatment with corticosteroids or NSAIDs during biopsy does not affect the expression of PD-L1 and it is therefore not necessary to take this treatment into account in this regard.

Indexed as

corticosteroidslung cancerNon-small cell lung cancer (NSCLC)non-steroidal anti-inflammatory drugs (NSAIDs)programmed death-ligand 1 (PD-L1)

Identifiers

PMID36237267
PMCPMC9552102
OpenAlexW4289540125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.